Literature DB >> 15776365

Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model.

Aleksandr S Lipatov1, Richard J Webby, Elena A Govorkova, Scott Krauss, Robert G Webster.   

Abstract

We studied the efficacy, in mice, of 2 H5 influenza vaccine viruses produced by reverse genetics. Mice were immunized with inactivated viruses and then inoculated with a human H5N1 1997 or 2003 virus or an avian H5N1 2001 virus. Vaccine viruses that we tested raised high levels of hemagglutination-inhibiting (1:160-1:1280) and virus-neutralizing (1:900-1:1900) antibodies on day 21 after a single dose of vaccine and decreased or prevented virus replication in mouse lungs; 54.5%-100% of immunized mice survived, whereas all control mice died. Protection was achieved despite antigenic differences and incomplete matching of the vaccine strain and the challenge virus. Therefore, high levels of cross-protection are predicted in the mouse model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15776365     DOI: 10.1086/428951

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines.

Authors:  Erich Hoffmann; Aleksandr S Lipatov; Richard J Webby; Elena A Govorkova; Robert G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

2.  Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.

Authors:  M A Rameix-Welti; F Agou; P Buchy; S Mardy; J T Aubin; M Véron; S van der Werf; N Naffakh
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.

Authors:  Wentao Gao; Adam C Soloff; Xiuhua Lu; Angela Montecalvo; Doan C Nguyen; Yumi Matsuoka; Paul D Robbins; David E Swayne; Ruben O Donis; Jacqueline M Katz; Simon M Barratt-Boyes; Andrea Gambotto
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

Authors:  Otfried Kistner; M Keith Howard; Martin Spruth; Walter Wodal; Peter Brühl; Marijan Gerencer; Brian A Crowe; Helga Savidis-Dacho; Ian Livey; Manfred Reiter; Ines Mayerhofer; Christa Tauer; Leopold Grillberger; Wolfgang Mundt; Falko G Falkner; P Noel Barrett
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

5.  Detection of expression of influenza virus receptors in tissues of BALB/c mice by histochemistry.

Authors:  Z-Y Ning; M-Y Luo; W-B Qi; B Yu; P-R Jiao; M Liao
Journal:  Vet Res Commun       Date:  2009-12       Impact factor: 2.459

6.  Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.

Authors:  Emmie de Wit; Vincent J Munster; Monique I J Spronken; Theo M Bestebroer; Chantal Baas; Walter E P Beyer; Guus F Rimmelzwaan; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice.

Authors:  Julia Steitz; Peter G Barlow; Jaber Hossain; Eun Kim; Kaori Okada; Tom Kenniston; Sheri Rea; Ruben O Donis; Andrea Gambotto
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

8.  Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge.

Authors:  Zhuo Li; Alaina J Mooney; Jon D Gabbard; Xiudan Gao; Pei Xu; Ryan J Place; Robert J Hogan; S Mark Tompkins; Biao He
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

Review 9.  Designing vaccines for pandemic influenza.

Authors:  Taisuke Horimoto; Yoshihiro Kawaoka
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

Review 10.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.